Technical Analysis for XRTX - XORTX Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.25 | -0.79% | -0.01 |
XRTX closed down 3.17 percent on Wednesday, November 20, 2024, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | -0.79% | |
| Narrow Range Bar | Range Contraction | -0.79% | |
| Inside Day | Range Contraction | -0.79% | |
| Oversold Stochastic | Weakness | -0.79% | |
| Gapped Up | Strength | -3.94% | |
| Oversold Stochastic | Weakness | -3.94% | |
| NR7 | Range Contraction | 1.28% | |
| Below Lower BB | Weakness | 1.28% | |
| Lower Bollinger Band Touch | Weakness | 1.28% | |
| Oversold Stochastic | Weakness | 1.28% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Up 1% | about 3 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
Sector: Technology
Industry: Data Storage
Keywords: Pharmaceutical Organ Systems Infection Kidney Disease Kidney Diabetic Nephropathy Autosomal Dominant Polycystic Kidney Disease
Classification
Sector: Technology
Industry: Data Storage
Keywords: Pharmaceutical Organ Systems Infection Kidney Disease Kidney Diabetic Nephropathy Autosomal Dominant Polycystic Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.0 |
| 52 Week Low | 1.09 |
| Average Volume | 67,320 |
| 200-Day Moving Average | 2.33 |
| 50-Day Moving Average | 1.57 |
| 20-Day Moving Average | 1.41 |
| 10-Day Moving Average | 1.35 |
| Average True Range | 0.16 |
| RSI (14) | 40.83 |
| ADX | 16.05 |
| +DI | 16.25 |
| -DI | 16.02 |
| Chandelier Exit (Long, 3 ATRs) | 1.31 |
| Chandelier Exit (Short, 3 ATRs) | 1.69 |
| Upper Bollinger Bands | 1.60 |
| Lower Bollinger Band | 1.21 |
| Percent B (%b) | 0.13 |
| BandWidth | 28.04 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.08 |
| MACD Histogram | -0.0102 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.38 | ||||
| Resistance 3 (R3) | 1.39 | 1.35 | 1.36 | ||
| Resistance 2 (R2) | 1.35 | 1.32 | 1.35 | 1.35 | |
| Resistance 1 (R1) | 1.31 | 1.30 | 1.29 | 1.30 | 1.35 |
| Pivot Point | 1.27 | 1.27 | 1.27 | 1.27 | 1.27 |
| Support 1 (S1) | 1.23 | 1.24 | 1.21 | 1.22 | 1.17 |
| Support 2 (S2) | 1.19 | 1.22 | 1.19 | 1.17 | |
| Support 3 (S3) | 1.15 | 1.19 | 1.16 | ||
| Support 4 (S4) | 1.14 |
